… Sulfated polymannuroguluronate (SPMG), a marine sulfated polysaccharide, has entered …
as the first anti-acquired immune deficiency syndrome (AIDS) drug candidate obtained from …

… of severe CNS disorders classified as the human immunodeficiency virus-1 … sulfated
polymannuroguluronate (SPMG), a novel anti-acquired immunodeficiency syndrome drug candidate …

… We herein report that sulfated polymannuroguluronate (SPMG), a novel anti-acquired
immunodeficiency syndrome drug candidate now in phase II clinical trial, significantly decreased …

… , an angioproliferation disease, is a form of malignancy which occurs in elderly or
immunosuppressed patients, and is often associated with acquired immune deficiency syndrome …

… Sulfated polymannuroguluronate (SPMG), a marine sulfated polysaccharide extracted from
… as the first anti-acquired immune deficiency syndrome (AIDS) drug candidate obtained from …

… Therefore, it is essential to isolate novel anti-HIV therapeutics … a novel candidate for the
development of anti-HIV-1 agents. … of marine sulfated polymannuroguluronate interfering with HIV…

… immunodeficiency virus (SIV) (6). SPMG has been approved as an anti-acquired immune
deficiency syndrome (AIDS) candidate, … The mechanisms of action underlying the anti-HIV-1 …

… Sulfated polymannuroguluronate (SPMG), a candidate anti-AIDS drug, inhibited HIV replication
and interfered with HIV entry into host T lymphocytes. SPMG has high binding affinity for …

… .24, 25 In addition, sulfated polymannuroguluronate (SPMG), a … great potential to be developed
into novel antiviral drugs. … -515) may be a novel anti-HIV candidate with low toxicity and …

… Sulfated polymannuroguluronate (SPMG) has entered the Phase II clinical trial as the first
anti-acquired immune deficiency syndrome (AIDS) drug candidate in China. Proliferation …